|
AU2013206411A1
|
|
Streptococcus Pyogenes Antigens
|
|
AU2013205807A1
|
|
Protective proteins of S. agalactiae combinations thereof and methods of using the same
|
|
AU2013203639A1
|
|
Small streptococcus pyogenes antiens and their use
|
|
WO2013083726A1
|
|
Aluminium compounds for use in therapeutics and vaccines
|
|
WO2012126879A1
|
|
Novel oprf/i fusion proteins, their preparation and use
|
|
GB201204360D0
|
|
Vaccine comprising aluminium adjuvant having low levels of contaminating heavy metal ions
|
|
WO2013135274A1
|
|
Aluminium compounds for use in therapeutics and vaccines
|
|
GB201121833D0
|
|
Aluminium compounds for use in therapeutics and vaccines
|
|
AU2011236092A1
|
|
Enterococcus Antigens
|
|
AU2011218655A1
|
|
S. Pneumoniae Antigens
|
|
AU2011204974A1
|
|
S. Agalactiae Antigens I + II
|
|
GB201112584D0
|
|
Formulations and processes for transcutaneous immunization and immunostimulation
|
|
CN103270047A
|
|
Oprf/i agents and their use in hospitalized and other patients
|
|
WO2011101465A1
|
|
Ic31 nanoparticles
|
|
WO2011045079A1
|
|
Hepatitis b virus specific human antibodies
|
|
EP2435063A2
|
|
Moraxella catarrhalis antigens
|
|
EP2405938A2
|
|
Nontypable haemophilus influenzae antigens
|
|
EP2424882A2
|
|
Peptides protective against e. faecalis, methods and uses relating thereto
|
|
EP2313116A1
|
|
Improved bacterial polysaccharide-polypeptide conjugate compositions
|
|
AU2009226949A1
|
|
Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
|
